{"disease":{"id":"hepatic-impairment-hi","name":"hepatic impairment hi"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06841315","title":"A Varegacestat Hepatic Impairment Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Immunome, Inc.","has_results":false},{"nct_id":"NCT06442436","title":"A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01231529","title":"GSK1349572 Hepatic Impairment Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT04252417","title":"HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"MedDay Pharmaceuticals SA","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}